Skip to main content


Details of the Drug
Generic Name:
Drug Type:
Growth factor
How the Drug is Given:

Subcutaneous (SC) injection or intravenously (IV); subcutaneously via the On-body Injector which is co-packaged with a single prefilled syringe

Pegfilgrastim-jmdb (FulphilaTM)
Pegfilgrastim-cbqv (UdenycaTM)
Pegfilgrastim-bmez (ZiextenzoTM)

Indications and Usage

Pegfilgrastim is FDA approved to

  • Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
  • Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).

Limitations of Use: Pegfilgrastim is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation


Side effects needing medical attention

Pain in the bones, arms, and legs; spleen rupture; Acute Respiratory Distress Syndrome (ARDS); allergic reactions such as rash, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate, and sweating; sickle cell crisis; kidney injury; increased white blood cell count (leukocytosis); and Capillary Leak Syndrome.


For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.